Latest news with #LesSulewski
CNBC
28-05-2025
- Business
- CNBC
Investors should buy the dip on this pharma stock with 40% upside, Truist says
Teva is positioning itself well for sharp gains in the near future after a decline this year, according to Truist Securities. The firm initiated shares of the generic drug maker with a buy rating. Analyst Les Sulewski set a price target of $25 per share, indicating upside of 41%. Shares of Teva have struggled this year, losing around 20%. However, Sulewski thinks that pullback created a buying opportunity for investors. "We think the company is well positioned to rival big pharma with its long-term durable growth strategy. With stock trading 25% off recent highs, we urge investors to accumulate," the analyst wrote. TEVA YTD mountain TEVA YTD chart Sulewski noted highlighted Teva's focus on margin improvement, which he said is being driven in part by: "High-margin specialty brands" such as Austedo and Ajovy, which are used to treat Huntington's disease and migraines, respectively. Plans to reduce manufacturing facilities to less than 22 from 34. "Mgmt continues to prioritize the company's Pivot to Growth plan, introduced 2023, with potential line of sight of ~300bps operating margin improvement by 2027," Sulewski added. "We look forward to hearing the next chapter for growth outlined in the company's upcoming Innovation and Strategy Day on May 29 when we anticipate mgmt to introduce an updated 5-year outlook, both figurative and thematic." The analyst noted that Teva's emphasis on specialty growth has not come at the cost of its identity as a "generics powerhouse," adding that the company "continues to benefit from new product launches, while ongoing portfolio cuts are helping to protect pricing and mix." Teva also has an innovative drug pipeline, which includes olanzapine to treat schizophrenia and duvakitug to treat ulcerative colitis and Crohn's disease. Teva shares gained more than 1% after Truist's bullish call. Most analysts are optimistic on Teva. LSEG data shows that eight of 11 covering the stock rate it a buy or strong buy. The average price target also signals upside of nearly 29%.
Yahoo
09-04-2025
- Business
- Yahoo
Pacira price target raised to $28 from $25 at Truist
Truist analyst Les Sulewski raised the firm's price target on Pacira (PCRX) to $28 from $25 and keeps a Hold rating on the shares. The firm cites a settlement with eVenus and counterparts for their generic entry of bupivacaine liposome injectable suspension – gExparel – and now envision peak Exparel sales of $740M by 2029, the analyst tells investors in a research note. The deal also removes the much debated overhang, Truist adds. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PCRX: Disclaimer & DisclosureReport an Issue Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives Pacira price target raised to $26 from $22 at RBC Capital Pacira price target raised to $65 from $48 at H.C. Wainwright Closing Bell Movers: Levi Strauss up 8% on earnings, futures find footing Pacira Pharmaceuticals Settles Patent Litigation with Fresenius Sign in to access your portfolio
